We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Tepnel Completes Acquisition of GenXTrak™ DNA Extraction Business from Whatman
News

Tepnel Completes Acquisition of GenXTrak™ DNA Extraction Business from Whatman

Tepnel Completes Acquisition of GenXTrak™ DNA Extraction Business from Whatman
News

Tepnel Completes Acquisition of GenXTrak™ DNA Extraction Business from Whatman

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Tepnel Completes Acquisition of GenXTrak™ DNA Extraction Business from Whatman"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The Board of Tepnel Life Sciences PLC has announced the completed acquisition of the GenXTrak DNA extraction business from UK-based Whatman plc for an undisclosed sum.

The Cambridge-based GenXTrak™ business will now operate within Tepnel's service division, offering extraction, purification, quantification and normalisation of clinical DNA samples.

The acquisition expands Tepnel's access to the pharmacogenomics testing market and positions the Company as one of Europe's largest providers of DNA extraction services.
 
Commenting on the acquisition, Ben Matzilevich CEO, said, "The acquisition of GenXTrak fits neatly into Tepnel's Research Products & Services division ceating additional capacity for our existing nucleic acid purification business."

"This business will provide access to European based customers and expand our menu of capabilities allowing us to handle a variety of sample types. An important component of Tepnel's strategic plan is to provide expanded capabilities in both genetic and protein analysis."

"In order to compete in these markets Tepnel must be able to provide low cost, high throughput services while meeting pharmaceutical standards. We plan to automate the Whatman facility to improve our competitive position."

"Once implemented in Cambridge we plan to expand these capabilities into our Edinburgh, Scotland and Stamford, USA facilities."

Advertisement